Showing posts with label Infections. Show all posts
Showing posts with label Infections. Show all posts

Saturday, 27 July 2013

Children with cancer receiving home care at greater risk for central line infections

Main Category: Cancer / Oncology
Also Included In: Pediatrics / Children's Health;  Infectious Diseases / Bacteria / Viruses;  Caregivers / Homecare
Article Date: 27 Jul 2013 - 0:00 PDT Current ratings for:
Children with cancer receiving home care at greater risk for central line infections
not yet ratednot yet rated

Pediatric cancer patients whose central lines are used to treat them at home develop three times as many dangerous bloodstream infections from their devices than their hospitalized counterparts, according to the results of a new Johns Hopkins Children's Center study.

Findings of the research, reported online in the journal Pediatric Blood & Cancer, provide valuable insight into the safety of central line uses outside the hospital and underscore the need to carefully evaluate the benefits and risk of sending a child home with one, the investigators say.

Furthermore, the results highlight the importance of better understanding the risks of at-home central line care and designing infection-prevention strategies.

"The health care system as a whole has spent a lot of time and energy studying hospital acquired bloodstream infections and has made serious progress in reducing their burden as a result. It is now time that we did the same for central line infections acquired outside the hospital," says lead investigator Michael Rinke, M.D., Ph.D., a pediatrician and safety expert at Johns Hopkins Children's Center.

"Some children with central lines do well at home and will have no complications, but based on our findings, we feel clinicians should remain vigilant when sending home certain special categories of pediatric cancer patients who face higher infection risk by virtue of their condition, device type or a combination of the two," Rinke adds.

A central line, or a central venous catheter, is a tube placed into a major blood vessel in the neck, chest or groin to serve as a temporary portal for injected medications and fluids. Inserted incorrectly, mishandled or simply handled too frequently, the central line can become a gateway for bacteria into the bloodstream, which can lead to serious complications, including organ damage and even death. Beyond the human toll, each infection can cost up to $45,000 in additional treatment, research has shown.

The study followed 319 children with cancer treated at Johns Hopkins who had central lines and received treatment between 2009 and 2010. Nearly all children were treated in the hospital at some point and sent home thereafter. In hospitalized children, there were 19 bloodstream infections over 8,682 days spent with a central line, compared with 55 such episodes over 84,705 days in the at-home group - or nearly three times the number of infections seen in hospitalized children.

"We have a wealth of data on the safety of central lines among hospitalized children and have designed solid protocols to reduce the risk of invasive bloodstream infections among such children, but we don't really have a good understanding of central line safety once the child leaves the hospital," says senior investigator Marlene Miller, M.D., M.Sc., director of Pediatric Quality and Safety at Johns Hopkins Children's Center. "Our study sheds some light on that issue."

Rinke and colleagues say several potent risk factors for infection emerged among children treated at home. Patients with recently placed central lines, those with recent bone marrow transplants and those with past infections were at highest risk, the study found. In addition, children with a type of central line tunneled under the skin that remains open, rather than implanted, in the chest, were found to be at greatest risk for infection. But because this type of central line is handled more frequently, it remains unclear whether the increased risk stems from the frequency of access or from the anatomic positioning of the device itself, the researchers say.

The investigators emphasize that central line care, even in the hospital, requires experienced clinicians and trained family members familiar with infection-prevention protocols - a level of care that is not always taught to families before the patient is discharged home.

"Teaching family members the 101 of central line cleaning and care can go a long way toward reducing infection risk and is something that should become part of the formal discharge routine in each and every hospital," Rinke says.

Such instructions, he adds, have been part of the Johns Hopkins Children's Center discharge protocol since 2010.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cancer / oncology section for the latest news on this subject.

The research was funded by the National Institutes of Health under grant number 5KL2RR025006 and by the Agency for Healthcare Research and Quality under grant number K08HS021282, with additional funding from the Children's Hospital Association.

Other Hopkins investigators on the study included Aaron Milstone, M.D., M.H.S.; Allen Chen, M.D., Ph.D., M.H.S.; Kara Mirski, B.A.; Elizabeth Colantuoni, Ph.D.; Miriana Pehar, R.N.; and Cynthia Herpst, R.N.

Johns Hopkins Medicine

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Medicine, Johns Hopkins. "Children with cancer receiving home care at greater risk for central line infections." Medical News Today. MediLexicon, Intl., 27 Jul. 2013. Web.
27 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Children with cancer receiving home care at greater risk for central line infections'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections

Main Category: Infectious Diseases / Bacteria / Viruses
Article Date: 27 Jul 2013 - 0:00 PDT Current ratings for:
Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections
not yet ratednot yet rated

In the commenting procedure on early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products (AMNOG), under certain circumstances drug manufacturers may submit to the Federal Joint Committee (G-BA) additional documents for dossiers. The Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed such additional information for two studies comparing the antibiotic fidaxomicin, which is used for diarrhoea caused by Clostridium difficile infections, with vancomycin.

In contrast to the first dossier assessment, the Institute now sees proof of a minor added benefit of fidaxomicin versus the appropriate comparator therapy in patients with severe or recurrent disease. An added benefit is still not proven in patients with mild disease; the manufacturer provided no new data for this indication.

Manufacturer dossier did not allow an overall conclusion

The antibiotic fidaxomicin (trade name: Dificlir) has been approved in Germany since December 2011 for the treatment of adults with diarrhoea caused by Clostridium difficile. IQWiG already presented an assessment pursuant to AMNOG in April 2013.

On the basis of the dossier submitted by the manufacturer, an advantage of fidaxomicin for the outcome "global cure" could be inferred for severe cases and recurrences. However, the magnitude of this advantage could not be inferred from the data presented. In addition, it could not be excluded that more severe side effects occurred precisely in these cases, thus outweighing advantages with regard to global cure. An overall conclusion on added benefit was therefore not possible.

Greater harm not proven in patients with severe disease

In the commenting procedure the manufacturer subsequently provided study results in a form that allows the weighing of positive and negative effects. Whereas no statistically significant difference between fidaxomicin and vancomycin was shown for all-cause mortality, the data provide proof of an added benefit for the outcome "global cure" in patients with severe or recurrent disease. In addition, in these subpopulations there is no suggestion of greater harm from fidaxomicin than from vancomycin.

An overall conclusion is thus possible: an added benefit of fidaxomicin versus the appropriate comparator therapy (vancomycin) is now proven for the treatment of patients with severe or recurrent Clostridium difficile infections. IQWiG classifies the extent of added benefit as minor.

An added benefit in patients with mild disease was not claimed by the manufacturer.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and the IQWiG dossier assessment, the G-BA conducted a commenting procedure in which the manufacturer submitted additional information. The G-BA subsequently commissioned IQWiG on 28 May 2013 to undertake a new assessment including the additional data.

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The Institute sent this addendum to the contracting agency (the G-BA) on 12 June 2013. The G-BA then decides on the extent of the added benefit in each case, thus completing the early benefit assessment.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.

The website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on fidaxomicin (English-language information [addendum and health information] will also be available in the near future; if you would like to be informed when this is published, please send an email to info@iqwig.de).

The G-BA website contains both general English-language information on benefit assessments pursuant to §35a Social Code Book V and specific German-language information on the assessment of fidaxomicin.

Addendum

Benefit assessment (dossier assessment)

Institute for Quality and Efficiency in Health Care

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Institute for Quality and Efficiency in Health Car. "Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections." Medical News Today. MediLexicon, Intl., 27 Jul. 2013. Web.
27 Jul. 2013. APA
Institute for Quality and Efficiency in Health Car. (2013, July 27). "Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/263932.php.

Please note: If no author information is provided, the source is cited instead.


'Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections

Main Category: Infectious Diseases / Bacteria / Viruses
Article Date: 27 Jul 2013 - 0:00 PDT Current ratings for:
Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections
not yet ratednot yet rated

In the commenting procedure on early benefit assessment pursuant to the German Act on the Reform of the Market for Medicinal Products (AMNOG), under certain circumstances drug manufacturers may submit to the Federal Joint Committee (G-BA) additional documents for dossiers. The Institute for Quality and Efficiency in Health Care (IQWiG) has now assessed such additional information for two studies comparing the antibiotic fidaxomicin, which is used for diarrhoea caused by Clostridium difficile infections, with vancomycin.

In contrast to the first dossier assessment, the Institute now sees proof of a minor added benefit of fidaxomicin versus the appropriate comparator therapy in patients with severe or recurrent disease. An added benefit is still not proven in patients with mild disease; the manufacturer provided no new data for this indication.

Manufacturer dossier did not allow an overall conclusion

The antibiotic fidaxomicin (trade name: Dificlir) has been approved in Germany since December 2011 for the treatment of adults with diarrhoea caused by Clostridium difficile. IQWiG already presented an assessment pursuant to AMNOG in April 2013.

On the basis of the dossier submitted by the manufacturer, an advantage of fidaxomicin for the outcome "global cure" could be inferred for severe cases and recurrences. However, the magnitude of this advantage could not be inferred from the data presented. In addition, it could not be excluded that more severe side effects occurred precisely in these cases, thus outweighing advantages with regard to global cure. An overall conclusion on added benefit was therefore not possible.

Greater harm not proven in patients with severe disease

In the commenting procedure the manufacturer subsequently provided study results in a form that allows the weighing of positive and negative effects. Whereas no statistically significant difference between fidaxomicin and vancomycin was shown for all-cause mortality, the data provide proof of an added benefit for the outcome "global cure" in patients with severe or recurrent disease. In addition, in these subpopulations there is no suggestion of greater harm from fidaxomicin than from vancomycin.

An overall conclusion is thus possible: an added benefit of fidaxomicin versus the appropriate comparator therapy (vancomycin) is now proven for the treatment of patients with severe or recurrent Clostridium difficile infections. IQWiG classifies the extent of added benefit as minor.

An added benefit in patients with mild disease was not claimed by the manufacturer.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and the IQWiG dossier assessment, the G-BA conducted a commenting procedure in which the manufacturer submitted additional information. The G-BA subsequently commissioned IQWiG on 28 May 2013 to undertake a new assessment including the additional data.

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The Institute sent this addendum to the contracting agency (the G-BA) on 12 June 2013. The G-BA then decides on the extent of the added benefit in each case, thus completing the early benefit assessment.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.

The website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on fidaxomicin (English-language information [addendum and health information] will also be available in the near future; if you would like to be informed when this is published, please send an email to info@iqwig.de).

The G-BA website contains both general English-language information on benefit assessments pursuant to §35a Social Code Book V and specific German-language information on the assessment of fidaxomicin.

Addendum

Benefit assessment (dossier assessment)

Institute for Quality and Efficiency in Health Care

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Institute for Quality and Efficiency in Health Car. "Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections." Medical News Today. MediLexicon, Intl., 27 Jul. 2013. Web.
27 Jul. 2013. APA
Institute for Quality and Efficiency in Health Car. (2013, July 27). "Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/263932.php.

Please note: If no author information is provided, the source is cited instead.


'Now proof of minor added benefit from Fidaxomicin in severe cases or recurrences of C. difficile infections'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Saturday, 20 July 2013

Researchers are defeating persistent bacteria known for causing infections in hospitals

Main Category: MRSA / Drug Resistance
Also Included In: Public Health
Article Date: 20 Jul 2013 - 0:00 PDT Current ratings for:
Researchers are defeating persistent bacteria known for causing infections in hospitals
not yet rated4 stars

The bacteria, Enterococcus faecalis, are the second-leading cause of hospital-associated infections in the U.S., said Lynn Hancock, associate professor of biology and leader of the research. His team has discovered how a regulatory system helps this bacteria resist a host's innate immune defense - a finding that may help develop novel drug compounds to fight the bacteria.

"Right now, we have very limited therapeutic interventions because the bacteria is highly resistant to not only antibiotics but a variety of other environmental stresses," Hancock said. "With the diminishing number of antibiotics that are effective at treating these types of infections, we need to come up with new strategies."

Enterococcus faecalis, or E. faecalis, is naturally found in the gastrointestinal tract of humans and other mammals. But outside the intestinal walls, the bacteria can cause bacteremia, urinary tract infections and endocarditis.

An added obstacle is that the bacteria are 100 to 1,000 times more resistant to lysozyme than other bacteria, Hancock said. Lysozyme is an infection-fighting substance that humans produce and is found in numerous body tissues, such as tear film, the urinary tract and saliva. The regulatory system of E. faecalis also makes it very resistant to other cellular stresses - such as elevated temperature, low pH and oxidative stress - that are part of a person's innate immune defense and help fight infection.

"Enterococcus has evolved sensing systems to find out the kind of environment it is in," said Sriram Varahan, doctoral student in microbiology and member of Hancock's research team. "It is a really rugged bacteria that is known to persist and survive in environments where other pathogens are unable to do so. Many infectious disease specialists have given it the moniker of being the cockroach of the microbial world."

By understanding the bacteria's regulatory network, the researchers hope to develop novel drug compounds that can block the bacterium's ability to sense and respond to the presence of lysozyme and other stresses during infection. To find the bacteria's weakness, the scientists focused on a protein called Eep. While studies have shown that Eep is important during infection, the Kansas State University researchers discovered how Eep contributes to an important stress response that the bacteria use to survive the host defense.

It is an important finding because now researchers can develop compounds that inhibit the Eep protein, which makes the bacteria susceptible to lysozyme and stops infection. When humans produce lysozyme to fight the bacteria, the bacteria will be unable to fight back.

"It's kind of like hitting it in the Achilles' heel," Hancock said. "Then it is very much compromised to establish infection."

While the bacteria are still able to live without the Eep protein, the bacteria need it to cause infection, Hancock said. Studies have shown that when the Eep is inactivated, bacteria are compromised nearly 10,000-fold in their ability to cause infection.

"The ability to interfere with a bacteria's ability to establish infection is going to become a more popular theme for treating infections rather than simply killing the bacteria," Hancock said. "When you put selective pressure on bacterial populations to live or die, they are really good at circumventing the drugs and getting around the killing mechanism."

For future research, Hancock and his team want to find what compounds are most effective at interfering with Eep to make the bacteria susceptible to lysozyme. They also want to study the SigV protein, which coordinates expression of target genes that are controlled by the Eep protein. Similar to Eep, if SigV is inactivated, then the target genes are not expressed and the bacteria do not become resistant to lysozyme. These target genes and proteins may also lead to new drug development possibilities.

"In the dawn of the post-antibiotic era, I think it is essential for us to have more options, rather than depending on a few silver bullets that are seemingly failing a lot in hospitals nowadays," Varahan said. "We have come up with new targets and hopefully they will work."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our mrsa / drug resistance section for the latest news on this subject.

The scientists recently published their research in the Journal of Bacteriology. The research was part of a $1.5 million five-year grant from the National Institutes of Health.

Other researchers involved include Vijayalakshmi Iyer, research associate in biology, and William Moore, a former doctoral student in microbiology.

View the Journal of Bacteriology publication at http://www.ncbi.nlm.nih.gov/pubmed/23645601.

Kansas State University

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University, Kansas State. "Researchers are defeating persistent bacteria known for causing infections in hospitals." Medical News Today. MediLexicon, Intl., 20 Jul. 2013. Web.
20 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Researchers are defeating persistent bacteria known for causing infections in hospitals'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Friday, 12 July 2013

Superbug Infections Found During Admission Screenings In Virginia

Main Category: MRSA / Drug Resistance
Also Included In: Infectious Diseases / Bacteria / Viruses;  Public Health
Article Date: 11 Jul 2013 - 1:00 PDT Current ratings for:
Superbug Infections Found During Admission Screenings In Virginia
5 starsnot yet rated

Antibiotic-resistant superbugs like carbapenem-resistant Enterobacteriaceae (CRE) present a challenge to healthcare professionals as patients move from different care settings and facilities, unknowingly spreading healthcare-associated infections. In a new study, researchers screened all patients for CRE at admission to a long-term acute care hospital (LTACH). They found patients colonized with CRE coming into the LTACH from hospitals, but they also found transmission occurring among patients in the LTACH. LTACHs provide similar care as hospitals but focus on patients who, on average, stay more than 25 days.

The findings of this study provide an indication of the prevalence of CRE in hospitalized patients in one specific region, as well as the frequency of transmission based on transitions between healthcare facilities. The study is published in the August issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

"Identification of asymptomatic CRE carriers admitted to LTACHs may help identify patients who could benefit from interventions that reduce risks for subsequent CRE transmission and break cycles of resistance that develop when patients move between healthcare facilities," said Costi Sifri, MD, an author of the study.

Recent research has shown that LTACHs can play important roles in the regional transmission of CRE. These facilities are reservoirs of healthcare-associated infections, since patients admitted to these facilities are highly susceptible to CRE colonization due to risk factors such as complex medical conditions, extended hospitalizations, invasive medical devices and unnecessary antibiotic use.

Researchers at the University of Virginia Health System prospectively screened patients admitted to a 40-bed central Virginia LTACH for CRE colonization. Additionally, weekly surveillance for CRE was performed on all patients in the facility. During the 24-month study period, 262 patients received care at the LTACH and 20 had positive CRE cultures.

The investigators identified six patients positive for CRE on admission who had no known history of CRE infection or colonization. Two of these patients were admitted from the affiliated academic hospital and four were admitted from four separate regional hospitals.

Additionally, six patients had a prior history of CRE colonization or infection and seven patients had no known history of CRE infection or colonization, but tested positive during hospitalization.

In a commentary published alongside the study, L. Silvia Munoz-Price, MD, Associate Professor of Medicine at University of Miami notes "healthcare professionals who work in this field are concerned with the inter-facility, inter-regional, and inter-continental spread of CREs. However, we are attempting to solve a population health problem by using snapshots of what occurs in our own hospitals or within a limited set of facilities where we have professional networks - over simplifications are hindering us from determining the extent in which all the contributing factors are affecting this dynamic population model."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our mrsa / drug resistance section for the latest news on this subject.

Jessica D. Lewis, Matthew Bishop, Brenda Heon, Amy J. Mathers, Kyle B. Enfield, Costi D. Sifri. "Admission Surveillance for Carbapenamase-Producing Enterobacteriaceae at a Long-TermAcute Care Hospital." Infection Control and Hospital Epidemiology 34:8 (August 2013).

Society for Healthcare Epidemiology of America

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Society for Healthcare Epidemiology of America. "Superbug Infections Found During Admission Screenings In Virginia." Medical News Today. MediLexicon, Intl., 11 Jul. 2013. Web.
11 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Superbug Infections Found During Admission Screenings In Virginia'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Superbug Infections Found During Admission Screenings In Virginia

Main Category: MRSA / Drug Resistance
Also Included In: Infectious Diseases / Bacteria / Viruses;  Public Health
Article Date: 11 Jul 2013 - 1:00 PDT Current ratings for:
Superbug Infections Found During Admission Screenings In Virginia
5 starsnot yet rated

Antibiotic-resistant superbugs like carbapenem-resistant Enterobacteriaceae (CRE) present a challenge to healthcare professionals as patients move from different care settings and facilities, unknowingly spreading healthcare-associated infections. In a new study, researchers screened all patients for CRE at admission to a long-term acute care hospital (LTACH). They found patients colonized with CRE coming into the LTACH from hospitals, but they also found transmission occurring among patients in the LTACH. LTACHs provide similar care as hospitals but focus on patients who, on average, stay more than 25 days.

The findings of this study provide an indication of the prevalence of CRE in hospitalized patients in one specific region, as well as the frequency of transmission based on transitions between healthcare facilities. The study is published in the August issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

"Identification of asymptomatic CRE carriers admitted to LTACHs may help identify patients who could benefit from interventions that reduce risks for subsequent CRE transmission and break cycles of resistance that develop when patients move between healthcare facilities," said Costi Sifri, MD, an author of the study.

Recent research has shown that LTACHs can play important roles in the regional transmission of CRE. These facilities are reservoirs of healthcare-associated infections, since patients admitted to these facilities are highly susceptible to CRE colonization due to risk factors such as complex medical conditions, extended hospitalizations, invasive medical devices and unnecessary antibiotic use.

Researchers at the University of Virginia Health System prospectively screened patients admitted to a 40-bed central Virginia LTACH for CRE colonization. Additionally, weekly surveillance for CRE was performed on all patients in the facility. During the 24-month study period, 262 patients received care at the LTACH and 20 had positive CRE cultures.

The investigators identified six patients positive for CRE on admission who had no known history of CRE infection or colonization. Two of these patients were admitted from the affiliated academic hospital and four were admitted from four separate regional hospitals.

Additionally, six patients had a prior history of CRE colonization or infection and seven patients had no known history of CRE infection or colonization, but tested positive during hospitalization.

In a commentary published alongside the study, L. Silvia Munoz-Price, MD, Associate Professor of Medicine at University of Miami notes "healthcare professionals who work in this field are concerned with the inter-facility, inter-regional, and inter-continental spread of CREs. However, we are attempting to solve a population health problem by using snapshots of what occurs in our own hospitals or within a limited set of facilities where we have professional networks - over simplifications are hindering us from determining the extent in which all the contributing factors are affecting this dynamic population model."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our mrsa / drug resistance section for the latest news on this subject.

Jessica D. Lewis, Matthew Bishop, Brenda Heon, Amy J. Mathers, Kyle B. Enfield, Costi D. Sifri. "Admission Surveillance for Carbapenamase-Producing Enterobacteriaceae at a Long-TermAcute Care Hospital." Infection Control and Hospital Epidemiology 34:8 (August 2013).

Society for Healthcare Epidemiology of America

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Society for Healthcare Epidemiology of America. "Superbug Infections Found During Admission Screenings In Virginia." Medical News Today. MediLexicon, Intl., 11 Jul. 2013. Web.
11 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Superbug Infections Found During Admission Screenings In Virginia'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Thursday, 11 July 2013

Outbreak Of Healthcare-Associated Infections Traced Back To Contaminated Ultrasound Gel

Main Category: Infectious Diseases / Bacteria / Viruses
Also Included In: MRI / PET / Ultrasound;  Respiratory / Asthma
Article Date: 11 Jul 2013 - 1:00 PDT Current ratings for:
Outbreak Of Healthcare-Associated Infections Traced Back To Contaminated Ultrasound Gel
not yet ratednot yet rated

After a 2011 outbreak of P. aeruginosa, investigators at Beaumont Health System near Detroit, Michigan determined contaminated ultrasound gel was the source of bacteria causing the healthcare-associated infection. The findings emphasize the need for increased scrutiny of contaminated medical products. This study is published in the August issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America.

"Ultrasound is a critical healthcare tool used every day in both diagnostic and interventional procedures," said Paul Chittick, MD, lead author of the study. "Although contaminated gel has been the cause of several documented outbreaks of infection, its potential role as a vehicle for spreading infections to patients is frequently overlooked."

In December 2011, researchers uncovered an unusual cluster of P. aeruginosa in the cardiovascular surgery intensive care unit during routine infection control surveillance. The bug is known to increase the risk of bloodstream and respiratory infections in immune-compromised individuals. Sixteen patients became colonized or infected with the bacteria, with all cases occurring in the respiratory tract. The outbreak was found to have stemmed from bottles of ultrasound transmission gel used during cardiovascular surgery. Following replacement of this gel with a sterile product, no further cases occurred.

Cultures of gel from a bottle in use in the operating room grew P. aeruginosa that was identical to the outbreak strain. It was originally thought that the gel had likely become contaminated during use. However, sealed bottles of gel grew the same P. aeruginosa strain, proving that the product was contaminated during the manufacturing process at the plant of Pharmaceutical Innovations.

As a result of this investigation, the FDA issued a warning about the gel, alerting the risk of infection posed by the product and instructing healthcare providers and systems not to use the infected products.

The Beaumont Health System investigators also recently published proposed guidelines in Infection Control and Hospital Epidemiology for the use of sterile versus nonsterile ultrasound gel. These guidelines include the need for sterile, single-dose ultrasound gel to be used for all invasive procedures and give appropriate storage and warming methods for the gel. Prior to this, no such guidelines existed in the United States.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.

Paul Chittick, Victoria Russo, Matthew Sims, Barbara Robinson-Dunn, Susan Oleszkowicz, Kara Sawarynski, Kimberly Powell, Jacob Makin, Elizabeth Darnell, Judith A. Boura, Bobby Boyanton, Jeffrey Band. "An Outbreak of Pseudomonas aeruginosa Respiratory Tract Infections Associated with Intrinsically Contaminated Ultrasound Transmission Gel." Infection Control and Hospital Epidemiology 34:8 (August 2013).

Society for Healthcare Epidemiology of America

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Society for Healthcare Epidemiology of America. "Outbreak Of Healthcare-Associated Infections Traced Back To Contaminated Ultrasound Gel." Medical News Today. MediLexicon, Intl., 11 Jul. 2013. Web.
11 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Outbreak Of Healthcare-Associated Infections Traced Back To Contaminated Ultrasound Gel'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here